ICON revenues climb 8% to $82.9m for Q3

Global contract clinical research organisation ICON today reported revenues up 8% to $82.9m (€63.8m) for its third quarter ended February 28, 2005.

In the nine months to February 28, 2005, net revenues were $240.7m (€185.5m), representing a 10% increase over net revenues of $219m (€168m) reported for the first nine months of last year.

Excluding the impact of acquisitions, revenue growth was 7% for the nine months ending February 28, 2005.

"The results for the quarter were satisfactory and in line with our expectations," commented chairman, Dr John Climax.

"The $106 million of net new business awards achieved during the quarter was good, confirming our view that the market for our services continues to be strong and that ICON is well positioned to capitalise on this potential."

ISEQ and NASDAQ-listed ICON has approximately 2,650 employees providing services to the pharmaceutical, biotech and medical device industries from 37 locations in 23 countries worldwide,